NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

NCT00598975 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor
Colorectal Cancer

Interventions

DRUG: NKTR-102 100 mg/m2
DRUG: NKTR-102 125 mg/m2
DRUG: Cetuximab

Sponsor

Nektar Therapeutics